Johns Hopkins HIV Guide
Vosevi
INDICATIONS
FDA
FDA
- Treatment of adult patients with chronic HCV infection without cirrhosis or compensated cirrhosis (Child-Pugh A) who have:
- Genotype 1, 2, 3, 4, 5 or 6 infection who have previously been treated with an HCV regimen containing an NS5A inhibitor
- Genotype 1a or 3 infection and have been previously treated with sofosbuvir without an NS5A inhibitor
There's more to see -- the rest of this topic is available only to subscribers.
Last updated: June 4, 2018
Citation
Dzintars, Kathryn. "Vosevi." Johns Hopkins HIV Guide, 2018. Johns Hopkins Guides, www.hopkinsguides.com/hopkins/view/Johns_Hopkins_HIV_Guide/545272/all/Vosevi.
Dzintars K. Vosevi. Johns Hopkins HIV Guide. 2018. https://www.hopkinsguides.com/hopkins/view/Johns_Hopkins_HIV_Guide/545272/all/Vosevi. Accessed June 1, 2023.
Dzintars, K. (2018). Vosevi. In Johns Hopkins HIV Guide https://www.hopkinsguides.com/hopkins/view/Johns_Hopkins_HIV_Guide/545272/all/Vosevi
Dzintars K. Vosevi [Internet]. In: Johns Hopkins HIV Guide. ; 2018. [cited 2023 June 01]. Available from: https://www.hopkinsguides.com/hopkins/view/Johns_Hopkins_HIV_Guide/545272/all/Vosevi.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Vosevi
ID - 545272
A1 - Dzintars,Kathryn,Pharm.D., BCPS
Y1 - 2018/06/04/
BT - Johns Hopkins HIV Guide
UR - https://www.hopkinsguides.com/hopkins/view/Johns_Hopkins_HIV_Guide/545272/all/Vosevi
DB - Johns Hopkins Guides
DP - Unbound Medicine
ER -
